March 21, 2006 -- A hepatitis C drug from Valeant Pharma failed the first of two planned Phase III trials; Teva will stop development of an oral version of Copaxone, its blockbuster multiple sclerosis drug; Praecis Pharma and Gilead entered into an anti-viral partnership; MGI Pharma began the first of two Phase III trials of Aquavan, a quick acting sedative; Indevus Pharma completed enrollment in its second Phase III trial for Sanctura XR, a once daily therapy for overactive bladder; Curis received the first of two preclinical milestone payments for its hair growth drug candidate; NicOx entered into a collaboration with Merck to develop new anti-hypertensive drugs; NitroMed announced (without explanation) that its senior management resigned; Threshold completed enrollment of a Phase II trial of a therapy for benign prostatic hyperplasia; Senetek sold its autoinjector business to Ranbaxy; and Novavax raised $38 million in a follow-on offering. The Centient Biotech 200™ was down 65 points to 4000.77, a 1.6% decline. More details...
